Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Q4

- PMLiVE

Novartis says migraine prevention drug clears phase III trial

Monthly injection co-developed with Amgen could be launched in 2018

Bayer symbol

Bayer and Merck take high-risk heart failure drug into phase III

Embarks on final study of vericiguat despite it not meeting objectives in phase II trial

- PMLiVE

NICE backs Bayer’s Eylea as first-line BRVO treatment

Recommends visual impairment therapy over current laser treatment

- PMLiVE

Novartis’ Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions

- PMLiVE

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

- PMLiVE

Chiesi’s Holoclar wins UK Prix Galien orphan drug award

Novartis and Astellas also scoop prizes at the prestigious ceremony

- PMLiVE

Novartis seeks first-line use for lung cancer drug Zykadia

Looks to go head-to-head with Pfizer/Merck KGaA’s Xalkori and Roche’s Alecensa

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

- PMLiVE

Amgen agrees to take Cytokinetics’ heart failure drug into phase III

Phase II results showed significant cardiac function benefit and no adverse safety signals

Novartis building

Anxiety over CAR-T follows Novartis closure of cell therapy unit

Firm maintains lead ALL project still on course for 2017 filings despite restructuring

- PMLiVE

Boehringer to add wireless data-collection to its Respimat inhaler

Joins forces with Qualcomm for COPD adherence collaboration

- PMLiVE

Vectura’s Flutiform flunks phase III COPD test

But new AirFluSal data demonstrates superior patient adherence over GSK’s Seretide/Advair

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links